• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Glaukos Corp (NY: GKOS )

    143.04 +1.29 (+0.91%)
    Official Closing Price Updated: 7:00 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Glaukos Corp

    < Previous 1 2 3 4 5 6 7 8 Next >
    Glaukos Stock Scores Rising Price Performance With Jump To 91 RS Rating
    On Tuesday, Glaukos stock hit an key technical milestone, with its Relative Strength Rating climbing to 91, up from 87 the day before. 
    Via Investor's Business Daily
    Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    Glaukos: Q2 Earnings Insights
    Glaukos (NYSE:GKOS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos missed estimated earnings by... 
    Via Benzinga
    Glaukos Receives FDA 510(k) Clearance For iStent infinite
    The U.S. 
    Via Benzinga
    Glaukos Announces FDA 510(k) Clearance of iStent infinite®
    From Glaukos Corporation
    Via Business Wire
    Glaukos: Q4 Earnings Insights
    Glaukos (NYSE:GKOS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos... 
    Via Benzinga
    Earnings Scheduled For February 22, 2022
    Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
    Via Benzinga
    Analyst Ratings For Glaukos
    Glaukos (NYSE:GKOS) has observed the following analyst ratings within the las... 
    Via Benzinga
    Glaukos Corporation Announces Second Quarter 2022 Financial Results
    From Glaukos Corporation
    Via Business Wire
    Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
    From Glaukos Corporation
    Via Business Wire
    The 6 Most Aggressive Growth Stocks to Buy in July
    These are the 6 most aggressive growth stocks to buy in July. They reflect huge potential growth in their sales and/or their earnings. 
    Via InvestorPlace
    Glaukos Announces Participation in the William Blair Growth Stock Conference
    From Glaukos Corporation
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
    Upgrades 
    Via Benzinga
    Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
    From Glaukos Corporation
    Via Business Wire
    Glaukos Corporation Announces First Quarter 2022 Financial Results
    From Glaukos Corporation
    Via Business Wire
    Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
    From Glaukos Corporation
    Via Business Wire
    Glaukos Announces the Release of its 2021 Sustainability Report
    From Glaukos Corporation
    Via Business Wire
    Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
    From Glaukos Corporation
    Via Business Wire
    Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View
    Sight Sciences Inc (NASDAQ: SGHT) has treated the first patient in the TRIDENT trial evaluating OMNI Surgical System compared to Glaukos Corp's (NYSE... 
    Via Benzinga
    Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
    From Glaukos Corporation
    Via Business Wire
    Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
    From Glaukos Corporation
    Via Business Wire
    Glaukos Announces Executive Leadership Changes
    From Glaukos Corporation
    Via Business Wire
    The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
    Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
    Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
    Via Benzinga
    Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
    From Glaukos Corporation
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
    Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
    Via Benzinga
    The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen... 
    Via Benzinga
    Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile
    Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The... 
    Via Benzinga
    Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
    From Glaukos Corporation
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.